16 A randomized, double-blind, placebo-controlled, two-period crossover study was one of the first to evaluate the combination of sitagliptin and metformin
The FDA warns that both CJC-1295 and ipamorelin are risky for immunogenicity, potentially causing life-threatening outcomes such as anaphylaxis.25 26 Cardiovascular concerns: Specifically concerning CJC-1295, the FDA warns of the risk of increased heart rate and systemic vasodilatory reaction, including flushing, warmth, and transient hypotension.25 27 Cancer: With their ability to increase the rate of cellular replication, growth hormone secretagogues in general are unsafe for cancer survivors and people with an active cancer diagnosis.28 Secretagogue use may elevate their risk for recurrence or worsen their prognosis
Side-effect logging is free in full: the 18 most common GLP-1 side effects plus unlimited custom symptoms, each on a 0-10 severity scale with timestamps, so a rough week becomes a record instead of a vague memory
Most research protocols utilize a standard dose administered 5-7 days a week
